-
Repotrectinib Approvals Expand to Include Patients with NTRK+ Solid Tumors
On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK-positive solid... -
Is Lung Cancer in Young Adults Hereditary?
Read time: 2 minutes The question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer... -
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed... -
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation... -
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these... -
Kicking Drug Resistance to the Curb in RET-positive Lung Cancer
Read time: 4 minutes Lung cancers that test positive for the RET biomarker are often treated with targeted therapy. While this type of treatment has improved the duration and... -
Leveraging Basic Science to Stop Drug Resistance in RET+ Lung Cancer
Advances in targeted therapies have allowed us to treat some types of lung cancer with mutations in specific genes (for example, EGFR, KRAS, and RET). This has given some patients... -
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutes It’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of... -
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at... -
FDA Grants Accelerated Approval for HER2+ Cancer Treatment
On April 5, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of fam-trastuzumab deruxtecan-nxki (Enhertu®) to treat patients with unresectable or... -
Caregivers: Planning the Self-Care Journey
This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase. The discussion features Michelle Bolden, founder... -
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Read time: 4 minutes I just returned from the Cancer Grand Challenges Summit, held March 5–8, 2024 in London, England. Cancer Grand Challenges was launched in 2020 as a...
Rare Mutations and Fusions